| 1 |
Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign：international guidelines for management of sepsis and septic shock: 2016[J]. Crit Care Med, 2017, 43(3): 486-552.
|
| 2 |
Goldenberg NM, Steinberg BE, Slutsky AS, et al. Broken barriers: a new take on sepsis pathogenesis[J]. Science Translational Med, 2011, 3(88): 88ps25-88ps25.
|
| 3 |
Ait-Oufella H, Maury E, Lehoux S, et al. The endothelium: physiological functions and role in microcirculatory failure during severe sepsis[J]. Intens Care Med, 2010, 36(8):1286-1298.
|
| 4 |
Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome[J]. Blood, 2003, 101(10): 3765-3777.
|
| 5 |
Hippenstiel S, Suttorp N. Interaction of pathogens with the endothelium[J]. Thromb Haemost, 2003, 89(1): 18-24.
|
| 6 |
Gianfranco B. Endothelial tight junctions: permeable barriers of the vessel wall[J]. Thromb Haemost, 2006, 96(1): 36-42.
|
| 7 |
国家老年疾病临床医学研究中心(解放军总医院) 《感染诱发的老年多器官功能障碍综合征诊治中国专家共识》撰写组. 《感染诱发的老年多器官功能障碍综合征诊治中国专家共识》[J]. 中华老年多器官疾病杂志，2018, 17(1): 3-13.
|
| 8 |
Wu Q, Ren J, Wu X, et al. Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: a prospective study[J]. J Crit Care, 2014, 29(3): 362-366.
|
| 9 |
Zakynthinos SG, Papanikolaou S, Theodoridis T, et al. Sepsis severity is the major determinant of circulating thrombopoietin levels in septic patients[J]. Crit Care Med, 2004, 32(4): 1004.
|
| 10 |
Segre E, Pigozzi L, Lison D, et al. May thrombopoietin be a useful marker of sepsis severity assessment in patients with SIRS entering the emergency department? [J]. Clin Chem Laboratory Med (CCLM), 2014: 1479-1483.
|
| 11 |
Lupia E, Bosco O, Mariano F, et al. Elevated thrombopoietin in plasma of burned patients without and with sepsis enhances platelet activation[J]. J Thromb Haemost, 2010, 7(6): 1000-1008.
|
| 12 |
Nawawi H, Osman NS, Annuar R, et al. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin[J]. Atherosclerosis, 2003, 169(2): 283-291.
|
| 13 |
Tchinda VHM, Tadem AD, Tako EA, et al. Severe malaria in Cameroonian children: correlation between plasma levels of three soluble inducible adhesion molecules and TNF-α[J]. Acta Tropica, 2007, 102(1): 0-28.
|
| 14 |
Kaushansky K. Thrombopoietin[J]. N Engl J Med, 1998, 339(11): 746-754.
|
| 15 |
Van der Meeren A, Mouthon MA, Vandamme M, et al. Combinations of cytokines promote smvival of mice and limit acute aadiation damage in concert with amelioration of vascular damage[J]. Radiat Res, 2004, 161(5): 549-559.
|
| 16 |
Wu Q, Ren J, Wu X, et al. Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: A prospective study[J]. J Crit Care, 2014, 29(3): 362-366.
|
| 17 |
Han JW, Kim KH, Kwun MJ, et al. Suppression of lung inflammation by the ethanol extract of Chung-Sang and the possible role of Nrf2[J]. BMC Complement Al tern Med, 2019, 19(1): 15.
|
| 18 |
Liu Z, Wang Y, Liu Y, et al. Typing of chronic ob structive pulmonary disease using high-resolution computed tomography and the association with smoking, arway inflammation，and common comorbidities[J]. Turk J Med Sci, 2018, 48(5): 945-951.
|
| 19 |
Cardier JE, Dempsey J. Thrombopoietin and its receptor, c-mpl, are constitutively expressed by mouse liver endothelial cells: evidence of thrombopoietin as a growth factor for liver endothelial cells[J]. Blood, 1998, 91(3): 923-929.
|
| 20 |
Stark AK, Sriskantharajah S, Hessel EM, et al. PI3K inhibitors in inflammation, autoimmunity and cancer[J]. Curr Opin Pharmacol, 2015, 23: 82-91.
|
| 21 |
Wang JY, Ye JY, Liang EY, et al. Thrombopoietin Prevents CoCl2-inducing Apoptosis of HUVEC through the PI3K/AKT Pathway[J]. J Exper Hematol, 2018, 26(2): 528.
|
| 22 |
Cheng HW, Chen YF, Wong JM, et al. Cancer cells increase endothelial cell tube formation and survival by activating the PI3K/Akt signalling pathway[J]. J Exper Clin Cancer Res, 2017, 36(1): 27.
|
| 23 |
Ramella R, Gallo MP, Spatola T, et al. A novel role of thrombopoietin as a physiological modulator of coronary flow[J]. Regulatory Peptides, 2011, 167(1): 5-8.
|
| 24 |
Chan KYY, Zhou L, Xiang P, et al. Thrombopoietin improved ventricular function and regulated remodeling genes in a rat model of myocardial infarction[J]. International Journal of Cardiology, 2013, 167(6): 2546-2554.
|
| 25 |
Baker JE, Su J, Koprowski S, et al. Thrombopoietin Receptor Agonists Protect Human Cardiac Myocytes from Injury by Activation of Cell Survival Pathways[J]. Journal of Pharmacology and Experimental Therapeutics, 2015, 352(3): 429-437.
|
| 26 |
Ilva T, Lund J, Porela P, et al. Early markers of myocardial injury: cTnI is enough[J]. Clinica Chimica Acta, 2009, 400(1-2): 0-85.
|
| 27 |
Grybauskiene R, Karciauskaite D, Brazdzionyte J, et al. Brain natriuretic peptide and other cardiac markers predicting left ventricular remodeling and function two years after myocardial infarction[J]. Medicina, 2007, 43(9): 708-715.
|
| 28 |
Singer M, Deutschman CS, Seymour CW, et al. The Third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 801-810.
|
| 29 |
Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign：international guidelines for management of sepsis and septic shock: 2016[J]. Intensive Care Med, 2017, 43(3): 304-377.
|
| 30 |
Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign：international guidelines for management of severe sepsis and septic shock, 2012[J]. Intensive Care Med, 2013, 39(2): 165-228.
|